Praxis Precision Medicines Engages Investors in February Conferences
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, is excited to announce its participation in two significant investor conferences this February. These events are poised to offer insights into the company’s groundbreaking work in transforming genetic insights into effective therapies.
Upcoming Conference Participation Details
Guggenheim Securities SMID Cap Biotechnology Conference
The first event is the Guggenheim Securities SMID Cap Biotechnology Conference, scheduled to take place in New York City on February 6, 2025. Praxis management will be featured in an engaging fireside chat at 2:30 p.m. EST. Investors and stakeholders can tune in to hear about Praxis's latest developments through a live webcast accessible on their website.
Oppenheimer’s Annual Healthcare Life Sciences Conference
Following that, the Oppenheimer 35th Annual Healthcare Life Sciences Conference will be held virtually on February 11, 2025. Praxis will once again participate in a fireside chat, where they will discuss their innovative approaches to treating CNS disorders at 11:20 a.m. EST. This online format provides an excellent opportunity for participants to engage from anywhere.
Opportunities for One-on-One Meetings
Both conferences also feature opportunities for interested investors to arrange one-on-one meetings with Praxis management. This personal interaction is valuable for stakeholders seeking in-depth information about the company’s strategies and vision. Investors are encouraged to reach out to their respective conference representatives for more information on scheduling these meetings.
Webcast Access and Future Replays
For those unable to attend the live events, both presentations will be available for replay. Interested parties can access the webcasts under the “Events and Presentations” section of the Praxis website. These replays will be hosted for 90 days, allowing ample time for stakeholders to dive into the discussions at their convenience.
About Praxis Precision Medicines
Praxis Precision Medicines stands out in the biopharmaceutical landscape as a clinical-stage company concentrated on addressing CNS disorders marked by neuronal excitation-inhibition imbalance. The company employs its proprietary platforms, including Cerebrum™ and Solidus™, to develop therapies tailored for both rare and common neurological disorders. With several clinical-stage product candidates in its portfolio, Praxis is committed to leading the charge in neurological health.
Frequently Asked Questions
What is the focus of Praxis Precision Medicines?
Praxis Precision Medicines is dedicated to developing therapies for CNS disorders by translating genetic insights into innovative treatments.
When are the investor conferences taking place?
The Guggenheim Securities conference is on February 6, 2025, and the Oppenheimer conference is on February 11, 2025.
How can investors access the conference webcasts?
Investors can view the live webcasts and replays on the Praxis website under the “Events and Presentations” section.
Are there opportunities for one-on-one meetings with management?
Yes, interested investors can arrange one-on-one meetings by contacting their Guggenheim or Oppenheimer representatives.
What are the unique platforms utilized by Praxis?
Praxis utilizes its proprietary platforms, Cerebrum™ and Solidus™, to discover and develop therapies targeting CNS disorders.
